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Background: Recent evidence suggests that when in an acidic milieu akin to that in the human stomach, clopidogrel forms S-nitrosothiols 
(RSNO) with anti-aggregatory and vasomodulatory effects. This effect relies on the availability of free thiol in the clopidogrel molecule. 
Ticagrelor however lacks a free thiol group as it is held within the ring structure of the molecule. Surprisingly, ticagrelor’s clinical 
effectiveness in large trials has been found to be attenuated in patients taking gastric acid suppressant medications. We sought to examine 
the effect of changing pH on the ability of ticagrelor to dissolve, react and subsequently inhibit platelets, then establish whether ticagrelor 
could form RSNO in an environment analogous to the gastric milieu.
methods: Ticagrelor (AstraZeneca UK) was prepared in solution by dissolving a 90mg tablet in saline. Dissolvability was also tested in an 
artificial stomach media. Platelet rich plasma was collected from healthy volunteers to establish platelet inhibition curves in response to 
both ADP and TRAP agonists using Multiplate® multiple electrode aggregometry.
results: In vitro, it was consistently evident that ticagrelor, once exposed to an acidic environment was then unable to inhibit platelet 
aggregation via P2Y12 receptor blockade compared to neutral pH. The ability of the parent drug to inhibit platelet aggregation was lost 
altogether at pH<3. However, ticagrelor did form RSNO as the pH dropped below 3, and to a greater degree than both clopidogrel and 
prasugrel induced RSNO formed previously. RSNO was produced easily, allowing us to compare its anti-platelet properties directly with the 
parent drug using Multiplate®.
conclusion: Ticagrelor’s platelet inhibitory response to ADP decreases after lowering of the pH in vitro. However in the presence of nitrite 
and decreasing pH in vitro, it readily formed ticagrelor induced RSNO which resulted in augmented platelet inhibition compared to ticagrelor 
alone. Ticagrelor dissolves readily in gastric media within 4 minutes to form RSNO. This is an exciting and novel finding that may explain 
some of the putative pleiotropic effects of ticagrelor and its rapid onset of action.
